{"url_path":"/sec/otlc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS, FINANCIAL STATEMENT SCHEDULES**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-023181-index.html","accession_number":"0001493152-26-023181","cik":"0000908259","ticker":"OTLC","issuer_name":"Oncotelic Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-023181-index.html","primary_entity_key":"0000908259","primary_entity_name":"Oncotelic Therapeutics, Inc."},"word_count":642,"has_tables":true,"body_markdown":"**ITEM\n6. EXHIBITS, FINANCIAL STATEMENT SCHEDULES**\n\n \n\nIn\nreviewing the agreements included as exhibits to this Quarterly Report, please remember that they are included to provide you with information\nregarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties\nto the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These\nrepresentations and warranties have been made solely for the benefit of the parties to the applicable agreement and:\n\n \n\n \n●\nshould\nnot in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties\nif those statements prove to be inaccurate;\n\n \n\n \n●\nhave\nbeen qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which\ndisclosures are not necessarily reflected in the agreement;\n\n \n \n \n\n \n●\nmay\napply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and\n\n \n \n \n\n \n●\nwere\nmade only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject\nto more recent developments.\n\n \n\n58\n\n \n\n \n\nAccordingly,\nthese representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.\nAdditional information about the Company may be found elsewhere in this Quarterly Report and the Company’s other public filings,\nwhich are available without charge through the SEC’s website at http://www.sec.gov.\n\n \n\nThe\nfollowing exhibits are included as part of this Quarterly Report, and should not be considered as a complete list of exhibits. A more\ncomplete list of previously filed Exhibits can be found with our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026:\n\n \n\n \n \n \n \n**Incorporated\nby Reference**\n\n**Exhibit\nNumber**\n \n**Description**\n \n**Form**\n \n**Filing\nDate**\n \n**Exhibit\nNumber**\n \n**Filed\nHerewith**\n\n \n \n \n \n \n \n \n \n \n \n \n\n10.1\n \n[Joint Development, Manufacturing and Licensing Agreement](https://www.sec.gov/Archives/edgar/data/908259/000149315226014831/ex10-1.htm)\n \n8-K\n \n\n04/02/2026\n\n \n10.1\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n10.2\n \n\n[Agreement and Plan of Merger](https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/ex2-1.htm)\n\n \n8-K\n \n\n05/05/2026\n\n \n2.1\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n10.3\n \n\n[Intellectual Property Assignment](https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/ex10-1.htm)\n\n \n8-K\n \n05/05/2026\n \n10.1\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n10.4\n \n\n[Intellectual Property Assignment and Grant-back Agreement](https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/ex10-2.htm)\n\n \n8-K\n \n05/05/2026\n \n10.2\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n10.5\n \n\n[Asset Transfer Agreement](https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/ex10-3.htm)\n\n \n8-K\n \n05/05/2026\n \n10.3\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n14.1\n \n[Corporate Code of Conduct and Ethics.](https://www.sec.gov/Archives/edgar/data/908259/000119312515111261/d847033dex141.htm)\n \n10-K\n \n3/30/2015\n \n14.1\n \n \n\n \n \n \n \n \n \n \n \n \n \n \n\n31.1\n \n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a).](ex31-1.htm)\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n31.2\n \n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a).](ex31-2.htm)\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n32.1\n \n[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.](ex32-1.htm)\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n32.2\n \n[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.](ex32-2.htm)\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.1\n \nInteractive\nData Files for the quarterly period ended March 31, 2026 and year ended December 31, 2025\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.INS\n \nInline\nXBRL Instance Document\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Schema\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Label Linkbase\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase\n \n \n \n \n \n \n \nX\n\n \n \n \n \n \n \n \n \n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n \n \n \n \n \n \n \nX\n\n \n\n*\nConfidential\ntreatment has been granted for portions of this Exhibit. Redacted portions filed separately with the Securities and Exchange Commission.\n\n+\nManagement\ncontract or compensatory plan or arrangement.\n\n \n\n59\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed\non its behalf by the undersigned, thereunto duly authorized.\n\n \n\n**ONCOTELIC\nTHERAPEUTICS INC.**\n \n\n \n \n \n\nBy:\n*/s/\nVuong Trieu*\n \n\n \nVuong\nTrieu, Ph.D.\n \n\n \nChief\nExecutive Officer and Director (Principal Executive Officer)\n \n\n \n \n \n\nDate:\nMay\n14, 2026\n \n\n \n \n \n\nBy:\n\n*/s/\nAmit Shah*\n \n\n \nAmit\nShah\n \n\n \n\nChief\nFinancial Officer\n\n(Principal\nFinancial and Accounting Officer)\n\n \n\n \n \n \n\nDate:\nMay\n14, 2026\n \n\n \n\n60"}